Nonclinical precedent Request an invite
Species
Cynomolgus monkey only
“The nonclinical toxicity profile of epcoritamab was established in a series of nonclinical safety studies in cynomolgus monkeys, the only cross-reactive toxicology species.”
✓ VerifiedFDA multi-discipline review, p. 53Source ↗
Why that species
Similar affinity for human and monkey CD3/CD20; no binding to dog, pig, rat, mouse CD20; CD3 not expected in other species
“The epcoritamab binding data indicates that among the species tested, the cynomolgus monkey is the only pharmacologically relevant species for toxicology studies.”
✓ VerifiedFDA multi-discipline review, p. 43Source ↗
Surrogate molecule
No surrogate; clinical molecule tested in monkey
“We agree that the cynomolgus monkey is a pharmacologically relevant nonclinical species to assess the toxicity of epcoritamab, and general toxicology studies in other species are not warranted.”
✓ VerifiedFDA multi-discipline review, p. 56Source ↗
Species: general tox
Cynomolgus monkey only (5-week study)
“The toxicity and toxicokinetics (TK) of epcoritamab were evaluated in a 5-week toxicity study in cynomolgus monkeys.”
✓ VerifiedFDA multi-discipline review, p. 45Source ↗
Species: DART
Not conducted; monkey EFD study waived due to high immunogenicity in cynomolgus monkeys; weight-of-evidence assessment
“An EFD toxicity study of epcoritamab in cynomolgus monkeys was waived for phase 3 trials and registration of epcoritamab across ICH regions (FDA, EMEA, and PMDA) given the high potential for immunogenicity of epcoritamab in cynomolgus monkeys.”
✓ VerifiedFDA multi-discipline review, p. 57Source ↗
Species: carcinogenicity
Not conducted (ICH S6(R1), S1A, S9)
“Carcinogenicity studies were not conducted for epcoritamab per ICHS6(R1), ICH S1A, and ICH S9 guidance.”
✓ VerifiedFDA multi-discipline review, p. 57Source ↗
Surrogate used in
No surrogate used; clinical molecule in cynomolgus monkey, the only relevant species
“The epcoritamab binding data indicates that among the species tested, the cynomolgus monkey is the only pharmacologically relevant species for toxicology studies.”
✓ VerifiedFDA multi-discipline review, p. 43Source ↗

Same question, other multispecifics

Bizengri

zenocutuzumab · HER2 x HER3
Cynomolgus monkey only

Blincyto

blinatumomab · CD19 x CD3
Chimpanzee (only relevant species, limited non-terminal studies) plus mouse with murine surrogate

Columvi

glofitamab · CD20 x CD3
Cynomolgus monkey only

Elrexfio

elranatamab · BCMA x CD3
Cynomolgus monkey only

Hemlibra

emicizumab · FIXa x FX
Cynomolgus monkey only

Imdelltra

tarlatamab · DLL3 x CD3
Cynomolgus monkey (pivotal); mouse surrogate muS757 for EFD and 1-month study

Kimmtrak

tebentafusp · CD3 x gp100 (TCR fusion)
No relevant species; in vitro human cell/tissue assays only

Korjuny

catumaxomab · EpCAM x CD3
No relevant species; limited single-dose mouse, rat, one cynomolgus; BiLu mouse surrogate

Lunsumio

mosunetuzumab · CD20 x CD3
Cynomolgus monkey only

Lynozyfic

linvoseltamab · BCMA x CD3
Cynomolgus monkey only

Ordspono

odronextamab · CD20 x CD3
Cynomolgus monkey only

Removab

catumaxomab · EpCAM x CD3
No relevant species; in vitro human cells plus mouse surrogate (BiLu); limited single-dose rodent/monkey

Rybrevant

amivantamab · EGFR x MET
Cynomolgus monkey only

Talvey

talquetamab · GPRC5D x CD3
Cynomolgus monkey only (tool molecule for pivotal tox); no rodent tox

Tecvayli

teclistamab · BCMA x CD3
Cynomolgus monkey only (rabbit used for SC local tolerance only)

Vabysmo

faricimab · VEGF-A x Ang-2
Cynomolgus monkey only for pivotal tox (rabbit dropped after early studies)

Ziihera

zanidatamab · HER2 x HER2 (biparatopic)
Cynomolgus monkey only

Summary across all 18 multispecifics →